Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11912-020-00908-9.pdf
Reference42 articles.
1. Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019;75:39–51.
2. Califano R, Kerr K, Morgan RD, Lo Russo G, Garassino M, Morgillo F, et al. Immune checkpoint blockade: a new era for non-small cell lung cancer. Curr Oncol Rep. 2016;18:59.
3. Rebuzzi SE, Leonetti A, Tiseo M, Facchinetti F. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. Immunotherapy. 2019;11:993–1003.
4. Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, et al. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019;15:2743–57.
5. Kim Y, Kim CH, Lee HY, Lee S-H, Kim HS, Lee S, et al. Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor. J Thorac Oncol. 2019;14:1608–18.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review;Medicine;2024-01-19
2. Application of radiomics in diagnosis and treatment of lung cancer;Frontiers in Pharmacology;2023-11-01
3. Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma;Seminars in Liver Disease;2023-11
4. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer;Frontiers in Immunology;2023-05-22
5. Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects;Cell Reports;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3